MammaPrint is performed on tumor tissue obtained by a healthcare professional from core needle biopsy or surgical resection. The tumor slides or FFPE (formalin fixed, paraffin embedded) tumor sample block is sent to the Agendia laboratory in Irvine, California where genomic analysis is conducted, and results are returned to the ordering physician to review with the patient. MammaPrint results are reported as a number (the MammaPrint Index) within four risk categories, each with their own clinical decision implications: UltraLow Risk, Low Risk, High Risk 1, and High Risk 2.